Close Menu

NEW YORK – Luminex said Monday that the US Food and Drug Administration has issued an Emergency Use Authorization (EUA) for its Aries SARS-CoV-2 Assay for rapid detection of the virus that causes COVID-19.

The assay runs on the FDA-cleared Aries System, a sample-to-answer molecular diagnostic platform that can perform 144 tests per day. It will allow hospital professionals to determine the appropriate course of treatment for patients suspected of having COVID-19 within approximately two hours, Luminex said.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

An Associated Press report says China refrained from releasing the SARS-CoV-2 genome for more than a week in January, frustrating the World Health Organization.

The Lancet and the New England Journal of Medicine have issued expressions of concern regarding the data used in two COVID-19 papers, the New York Times reports. 

Researchers have sequenced the genome of the mayfly, garnering insight into how insects evolved wings, Science reports.

In Genome Research this week: gene expression in primate brain regions, inversions and breakpoint inverted repeats in the human genome, and more.